Documentos relacionados

1. Two eminently treatable genetic metabolic myopathies.
2. The new horizons for treatment of Late-Onset Pompe Disease (LOPD).
3. Novel autophagic vacuolar myopathies: Phenotype and genotype features.
4. Response to Comments on "Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice".
5. Insight into broad substrate specificity and synergistic contribution of a fungal α-glucosidase in Chinese Nong-flavor daqu.
6. The earliest enzyme replacement for infantile-onset Pompe disease in Japan.
7. Enzyme replacement therapy for infantile-onset Pompe disease.
8. Therapeutic thoroughfares for adults living with Pompe disease.
9. Spectrum of metabolic myopathies.
10. Fluorescence detection of 4-nitrophenol and α-glucosidase activity based on 4-nitrophenol-regulated fluorescence of silicon nanoparticles.